Insilico Says AI Drug Rentosertib Cut Biological Age 3-4 Years in 42-Patient Study
Updated
Updated · ground.news · Sep 8
Insilico Says AI Drug Rentosertib Cut Biological Age 3-4 Years in 42-Patient Study
3 articles · Updated · ground.news · Sep 8
Summary
Six proteomic aging clocks in a 42-patient, 12-week clinical study showed Insilico Medicine's rentosertib lowered predicted biological age by 3-4 years.
Rentosertib was being tested for idiopathic pulmonary fibrosis, and lung function improved in a dose-dependent pattern alongside the age-marker shifts.
Nature Biotechnology published the findings, which Insilico framed as evidence that an AI-designed drug can show geroprotective effects in a human disease trial.
The result remains preliminary because the Phase 2a study was small, leaving larger trials to determine whether the anti-aging signal holds beyond this lung-disease setting.